Entry118.86→Now119.65
Owns Incyte: profitable biotech despite EPS dip. Open original source
INCY Incyte Genomics Inc Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
18:57
Nov 06
Nov 06
Dmitry Solodin
Owns Incyte: profitable biotech despite EPS dip.
Solodin says he invests in a similar profitable biotech, transcribed as 'Интии/Инсия' and most likely Incyte. Revenue and profit are growing. EPS dipped last quarter, which needs checking, but the company stays profitable.
INCY
Incyte Genomics Inc
Long
2ND
Position: Holding
—
06:26
Aug 21
Aug 21
Анатолий Радченко | Финансовый кружок
Incyte cheap with high margin growth.
Incyte is cheap at 14-16x earnings with stable revenue from Jakafi, rising EPS, buybacks, 30% operating margin, about 30% sales growth, and DCF value near 140-150.
INCY
Incyte Genomics Inc
Long
1ST
—
—
16:04
Aug 07
Aug 07
Dmitry Solodin
Incyte cup-and-handle breakout
Incyte (INCY) is forming a cup-and-handle pattern with accelerating fundamentals, and he expects a breakout to new highs.
INCY
Incyte Genomics Inc
Long
1ST
—
—
About INCY Investor Commentary
Across the available history and selected sources, Buzzberg tracks INCY (Incyte Genomics Inc) across 11 sources: 8 bullish vs 0 bearish calls from 12 authors. Historical directional balance: 36% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 22 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: Dmitry Solodin, Гоша.